Clinical Research

South Shore Neurologic Associates Clinical Research Department has focused on bringing groundbreaking medication opportunities to patients in need. The clinical trials are designed to help evaluate medications & devices prior to FDA approval, as well as further evaluate post-approval medications. Bringing high-tech research to our community provides opportunities that allow our patients access to medications & devices that are on the cutting edge of science opening new avenues for those who are unable to obtain relief from other therapies. We have participated in many clinical trials for Multiple Sclerosis, Parkinson's disease, Huntington's disease, and compassionate access treatments for ALS.

Medical Staff:

Lori Fafard, RN, BSN, CNRN, MSCN, CCRP
Laura Graffitti, RN, BSN, CNRN, MSCN, CCRP
Stephanie Galarza, SC
Erin Vacey, Clinical Assistant

Enrolling Studies as of 06/21/2017 

Study Name

Study Coordinator(s)

Phone Extension

Study Description

Affinity 215MS202 Laura 2207 A Multicenter, Randomized, Double-Blind, Placebo-ControlledStudy in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy andSafety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-ModifyingTherapies
Evolve MS-2 Stephanie 2247 Multicenter, tolerability of alks3700; new start tecfidera patients
BIOGEN 109MS414 Laura 2207 Multicenter, Double Blind, Placebo Controlled Study of Montelukast on GI Tolerability in Patients With RRMS on Tecfidera. AGES 18+
CHUGAI NMO/NMOSD Lori 2205 NMO: Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Phase III Study to Evaluate The Efficacy and Safety of SA237 as Mono-Therapy in Patients With Neuromyelitis Optica (NMO) AND Neuromyelitis Optica Spectrum Disorder (NMOSD)
ESTEEM 109-MS-401 Laura 2207 RRMS; Observational New Start Tecfidera LT Benefit; Determine Reasons For SAE'S, DMTS Routine Prescription Utilization and Efficacy
Fluent CFTY720DUS40
Stephanie 2247 Gilenya Observational
MN-166-ALS-1202 Ibudilast Stephanie 2247 A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)
PASSAGE CFTY720D2403 Laura 2207 Observational Study New Start All MS DMTS
Ultimate II TG1101-RM302 Stephanie 2247 Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects

Locations this service is offered at:

Patchogue
77 Medford Avenue (Route 112)
Patchogue, NY 11772

Tel: 631-758-1910
Fax: 631-750-1014